Senior specialist in Biomedical Sciences (Doctoral training 2012-2017) with the International Mention in the Division of Sciences of the Health, (2015-2017) academic year and, a Full Member of the International Society for Autism Research (INSAR). My principal research goal is the brain metabolism in Autism Spectrum Disorders (ASD), which is researching through the project “Magnetic resonance spectroscopy applied to diagnosis clinical in people with autism spectrum disorders.” in Neurochemistry and Neuroimaging Lab. Group, (Faculty of Medicine, ULL), since 2012. My research lines include: a) the screening of activity brain neurometabolites in vivo, particularly as Autism spectrum disorders (ADS) disruptors; b) the characterization of brain metabolism through spectroscopy-based (1H-MRS), and c) the elucidation of the mode-of-action of potential ASD disruptors in kinetic models. A long list of publications in congresses international and national reveals my research results.
My short-term goals (2-5 years) are focusing on developing a biomarker for diagnosis in ASD. This provides insight into the characterization of biomarkers for ASD and therapeutic implications for this patient population. In this sense, my research goals will align with the Drug discovery research and lead new collaborations that I which ones benefit from.
Senior specialist in Biomedical Sciences (Doctoral training 2012-2017) with the International Mention in the Division of Sciences of the Health, (2015-2017) academic year and, a Full Member of the International Society for Autism Research (INSAR). My principal research goal is the brain metabolism in Autism Spectrum Disorders (ASD), which is researching through the project “Magnetic resonance spectroscopy applied to diagnosis clinical in people with autism spectrum disorders.” in Neurochemistry and Neuroimaging Lab. Group, (Faculty of Medicine, ULL), since 2012. My research lines include: a) the screening of activity brain neurometabolites in vivo, particularly as Autism spectrum disorders (ADS) disruptors; b) the characterization of brain metabolism through spectroscopy-based (1H-MRS), and c) the elucidation of the mode-of-action of potential ASD disruptors in kinetic models. A long list of publications in congresses international and national reveals my research results.
My short-term goals (2-5 years) are focusing on developing a biomarker for diagnosis in ASD. This provides insight into the characterization of biomarkers for ASD and therapeutic implications for this patient population. In this sense, my research goals will align with the Drug discovery research and lead new collaborations that I which ones benefit from.